Chemotherapy for pancreatic cancer typically lasts about 6 months when the goal is to cure or prevent recurrence. That timeline shifts significantly depending on whether chemo is given before surgery, after surgery, or for advanced disease that can’t be surgically removed. Here’s what to expect for each situation.
The Standard Course: 12 Cycles Over 6 Months
For patients whose pancreatic cancer can be surgically removed, the standard of care is 12 cycles of a regimen called modified FOLFIRINOX, given every two weeks. That adds up to roughly 6 months of treatment. These 12 cycles may happen entirely after surgery (adjuvant), entirely before surgery (neoadjuvant), or split between the two.
The 12-cycle benchmark exists because studies haven’t shown that doing more than 12 cycles improves outcomes, and continuing beyond that point raises the risk of lasting nerve damage and other side effects from cumulative drug exposure. Some patients don’t complete all 12 cycles due to low blood cell counts or other complications that force delays or early stopping. Finishing 10 or 11 cycles is common and not necessarily cause for alarm.
Chemo Before Surgery
When chemotherapy is given before surgery, it usually lasts at least 3 months. Research on borderline resectable tumors (cases where surgery is possible but the tumor sits close to major blood vessels) shows that patients who received 3 or more months of chemo before surgery had significantly better survival than those who received less. In one study, patients who completed at least 8 cycles of FOLFIRINOX before surgery had the best outcomes, with median survival stretching well beyond 3 years. Going past 12 cycles before surgery didn’t add a survival benefit compared to 8 to 11 cycles.
The practical takeaway: most patients receive somewhere between 2 and 4 months of chemo before surgery, then complete the remaining cycles afterward to reach the full course.
Chemo After Surgery
After a successful surgical resection, chemotherapy typically begins once you’ve recovered enough, usually 4 to 8 weeks post-surgery. If you didn’t receive any chemo before the operation, you’ll go through the full 6 months of treatment afterward. If you already had some cycles before surgery, the remaining cycles are completed to reach the standard 12 total.
For patients who can’t tolerate the more intensive FOLFIRINOX regimen, an alternative combination using gemcitabine is often used instead. This runs on a 28-day cycle, with infusions on specific days followed by rest periods, and also continues for approximately 6 months.
Advanced or Metastatic Disease
When pancreatic cancer has spread to other organs or is locally advanced and can’t be removed surgically, chemotherapy doesn’t follow a fixed timeline. Treatment continues until one of two things happens: the cancer starts growing again despite the drugs, or the side effects become too severe to continue. This means some patients stay on chemo for many months, while others may only tolerate a few cycles.
The most common reasons treatment stops are fatigue, nerve pain in the hands and feet (neuropathy), and dangerously low blood counts. Doctors monitor for these closely. Median overall survival for patients with metastatic pancreatic cancer who receive only chemotherapy is around 16 months, though this varies widely. Some patients transition to a less intense “maintenance” regimen after the initial months of treatment, which can extend how long they remain on therapy while keeping side effects manageable.
What a Treatment Day Looks Like
A single infusion session can range from under an hour to 8 or more hours depending on the regimen. FOLFIRINOX is one of the longer ones. The clinic visit itself involves getting blood drawn, waiting for lab results, seeing your oncologist, and then sitting for the infusion. Plan for most of the day.
With FOLFIRINOX, you also go home with a small portable pump that continues delivering one of the drugs over the next 46 hours. That means you’ll be connected to the pump for about two days after each clinic visit before returning to have it disconnected. This is a detail many patients don’t anticipate, and it’s worth factoring into your planning for work, childcare, and daily life during treatment weeks.
Why Timelines Vary
The numbers above represent standard targets, but real treatment timelines are rarely perfectly smooth. Delays happen frequently. Low white blood cell counts are the most common reason a scheduled infusion gets pushed back a week. Infections, severe nausea, or neuropathy can also pause treatment. Some patients need dose reductions partway through, which may change the schedule. A 6-month course that started in January might not wrap up until August or September once delays are factored in.
Your oncologist will also reassess the plan at regular intervals, typically with imaging scans every 2 to 3 months. These scans determine whether the cancer is responding, stable, or growing. If the cancer progresses during treatment, the team may switch to a different drug combination, which resets the timeline. If the cancer is responding well before surgery, the surgical date might be moved up or pushed back depending on imaging results.